Exact Sciences Corporation Stock News

Exact Sciences Corporation (NASDAQ:EXAS ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 1:30 PM EDT Company Participants Aaron Bloomer - Chief Financial Officer Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Presentation Brandon Couillard MD & Equity Analyst All right. Good afternoon.

ST. LOUIS--(BUSINESS WIRE)--Geneoscopy announced that Exact Sciences has withdrawn its motion for a preliminary injunction regarding the '781 patent and the ‘746 patent.

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast. Wells Fargo Healthcare Conference, Boston Fireside chat on Wednesday, September 3, 2025 at 1:30 p.m. ET Baird Global Healthcare Conf...

Cathie Wood is one of the country's best known growth investors, but sometimes, she acts like an umbrella-toting value investor. The Ark Invest co-founder, CEO, and chief investment officer is often adding to some of her sinking positions on any given market day, and that's exactly what she did on the final trading day of last week.

We added key positions in Masimo, Exact Sciences, Eli Lilly, Penumbra, and Edwards Lifesciences, each with strong growth drivers and market leadership. Our investment in Masimo is supported by divestiture of non-core assets, new leadership, and a focus on high-growth hospital monitoring technologies. Eli Lilly remains a core holding due to its leadership in diabetes and obesity treatments, robu...

Exact Sciences Corporation (NASDAQ:EXAS ) Q2 2025 Earnings Conference Call August 6, 2025 5:00 PM ET Company Participants Aaron Bloomer - Chief Financial Officer Derek Leckow - Vice President of Investor Relations Kevin T. Conroy - Chairman of the Board & CEO Conference Call Participants Andrew Frederick Brackmann - William Blair & Company L.L.C.

Exact Sciences (EXAS) Q2 Revenue Up 16%

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, and Freenome, a biotechnology company pioneering an early cancer detection platform, today announced they have entered into an agreement under which Exact Sciences will acquire exclusive rights in the United States to current and future versions of Freenome's blood-b...